The Pulmonary Circulation in Heart Failure;La circulación pulmonar en la insuficiencia cardiaca

Revista Espanola de Cardiologia

Volumn 63, Issue 3, 2010, Pages 334-345

  Delgado, Juan F ^a  

^a Cardiología Hospital Universitario 12   (Spain)

Author keywords

Heart failure; Heart transplant; Pulmonary hypertension; Vasodilators

Indexed keywords

VASODILATOR AGENT;

ARTICLE; FIBROMUSCULAR DYSPLASIA; HEART FAILURE; HEART HYPERTROPHY; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG CIRCULATION; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; HEART TRANSPLANTATION; PATHOLOGY;

HEART FAILURE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; PULMONARY CIRCULATION;

EID: 77950565871     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70092-0     Document Type: Article

References (76)

1. Segovia J., Bermejo J., Alfonso F., and Heras M. Corazón derecho y circulación pulmonar: ¿una circulación menor?. Rev Esp Cardiol 63 (2010) 77-80
2. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (2009) 1573-1619
3. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barberá J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30 (2009) 2493-2537
4. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54 Suppl (2009) S43-S54
5. Hoeper M.M., Barbera J.A., Channick R.N., Hassoun P.M., Lang I.M., Manes A., et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 54 Suppl (2009) S85-S96
6. Kovacs G., Berghold A., Scheidl S., and Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34 (2009) 888-894
7. Moraes D.L., Colucci W.S., and Givertz M.M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102 (2000) 1718-1723
8. Greyson C. Ventrículo derecho y circulación pulmonar: conceptos básicos. Rev Esp Cardiol 63 (2010) 81-95
9. Gehlbach B.K., and Geppert E. The pulmonary manifestations of left heart failure. Chest 125 (2004) 669-682
10. Enriquez-Sarano M., Rossi A., Seward J.B., Bailey K.R., and Tajik A.J. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 29 (1997) 153-159
11. Schwammenthal E., Vered Z., Agranat O., Kaplinsky E., Rabinowitz B., and Feinberg M.S. Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study. Circulation 102 (2000) 2378-2384
12. Capomolla S., Febo O., Guazzotti G., Gnemmi M., Mortara A., Riccardi G., et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 19 (2000) 426-438
13. Khan A., Moe G.W., Nili N., Rezaei E., Eskandarian M., Butany J., et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 43 (2004) 68-76
14. Stefanadis C., Dernellis J., and Toutouzas P. A clinical appraisal of left atrial function. Eur Heart J 22 (2001) 22-36
15. Cooper C.J., Landzberg M.J., Anderson T.J., Charbonneau F., Creager M.A., Ganz P., et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 93 (1996) 266-271
16. Ontkean M., Gay R., and Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69 (1991) 1088-1096
17. Cody R.J., Haas G.J., Binkley P.F., Capers Q., and Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85 (1992) 504-509
18. Wagenvoort C.A., and Mooi W.J. Congestive vasculopathy. In: Wagenvoort C.A., and Mooi W.J. (Eds). Biopsy pathology of the pulmonary vasculature (1989), Chapman & Hall Medical, London 171-198
19. Gómez-Sánchez M.A., Mestre de Juan M.J., Gómez-Pajuelo C., López J.I., Díaz de Atauri M.J., and Martínez-Tello F.J. Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study. Chest 95 (1989) 325-331
20. Goodale Jr. F., Sanchez G., Friedlich A.L., Scannell J.G., and Myers G.S. Correlation of pulmonary arteriolar resistance with pulmonary vascular changes in patients with mitral stenosis before and after valvulotomy. N Engl J Med 252 (1955) 979-983
21. Delgado J.F., Conde E., Sánchez V., López-Ríos F., Gómez-Sánchez M.A., Escribano P., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 7 (2005) 1011-1016
22. Bhatia S.J., Kirshenbaum J.M., Shemin R.J., Cohn L.H., Collins J.J., Di Sesa V.J., et al. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation 76 (1987) 819-826
23. Delgado J.F., Gómez-Sánchez M.A., Sáenz de la Calzada C., Sánchez V., Escribano P., Hernández-Afonso J., et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 20 (2001) 942-948
24. Greenberg M.L., Uretsky B.F., Reddy P.S., Bernstein R.L., Griffith B.P., Hardesty R.L., et al. Long-term hemodynamic follow-up of cardiac transplant patients treated with cyclosporine and prednisone. Circulation 71 (1985) 487-494
25. Tamburino C., Corcos T., Feraco E., Leger P., Desruennes M., Vaissier E., et al. Hemodynamic parameters one and four weeks after cardiac transplantation. Am J Cardiol 63 (1989) 635-637
26. Zener J.C., Hancock E.W., Shumway N.E., and Harrison D.C. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol 30 (1972) 820-826
27. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., and Redfield M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53 (2009) 1119-1126
28. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-2550
29. Abramson S.V., Burke J.F., Kelly Jr. J.J., Kitchen III J.G., Dougherty M.J., Yih D.F., et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 116 (1992) 888-895
30. Cappola T.P., Felker G.M., Kao W.H., Hare J.M., Baughman K.L., and Kasper E.K. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 105 (2002) 1663-1668
31. Butler J., Chomsky D.B., and Wilson J.R. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 34 (1999) 1802-1806
32. Di Salvo T.G., Mathier M., Semigran M.J., and Dec G.W. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 25 (1995) 1143-1153
33. Arena R., Myers J., Abella J., Peberdy M.A., Bensimhon D., Chase P., et al. Development of a ventilatory classification system in patients with heart failure. Circulation 115 (2007) 2410-2417
34. Lewis G.D., Shah R.V., Pappagianopolas P.P., Systrom D.M., and Semigran M.J. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail 1 (2008) 227-233
35. Grigioni F., Potena L., Galie N., Fallani F., Bigliardi M., Coccolo F., et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 25 (2006) 1241-1246
36. Ghio S., Gavazzi A., Campana C., Inserra C., Klersy C., Sebastiani R., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37 (2001) 183-188
37. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., et al. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Rev Esp Cardiol 61 (2008) 1329 e1-3370 e1
38. Healey J.S., Davies R.A., and Tang A.S. Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. J Heart Lung Transplant 23 (2004) 650-652
39. Schulze-Neick I., Luther Y.C., Ewert P., Lehmkuhl H.B., Hetzer R., and Lange P.E. End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation 78 (2004) 1237-1238
40. Califf R.M., Adams K.F., McKenna W.J., Gheorghiade M., Uretsky B.F., McNulty S.E., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
41. Hare J.M., Shernan S.K., Body S.C., Graydon E., Colucci W.S., and Couper G.S. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation 95 (1997) 2250-2253
42. Bocchi E.A., Bacal F., Auler Junior J.O., Carmone M.J., Bellotti G., and Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 74 (1994) 70-72
43. Kieler-Jensen N., Ricksten S.E., Stenqvist O., Bergh C.H., Lindelov B., Wennmalm A., et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13 (1994) 366-375
44. Rich G.F., Murphy Jr. G.D., Roos C.M., and Johns R.A. Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 78 (1993) 1028-1035
45. Ardehali A., Hughes K., Sadeghi A., Esmailian F., Marelli D., Moriguchi J., et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 72 (2001) 638-641
46. Alaeddini J., Uber P.A., Park M.H., Scott R.L., Ventura H.O., and Mehra M.R. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 94 (2004) 1475-1477
47. Gómez-Sánchez M.A., Sánchez de la Calzada C., Subias P.E., Jiménez J.F.D., Salvador M.L., González A.A., et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail 6 (2004) 615-617
48. Guazzi M., Tumminello G., Di Marco F., Fiorentini C., and Guazzi M.D. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44 (2004) 2339-2348
49. Lewis G.D., Lachmann J., Camuso J., Lepore J.J., Shin J., Martinovic M.E., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007) 59-66
50. Lewis G.D., Shah R., Shahzad K., Camuso J.M., Pappagianopoulos P.P., Hung J., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555-1562
51. Guazzi M., Samaja M., Arena R., Vicenzi M., and Guazzi M.D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50 (2007) 2136-2144
52. Goldsmith S.R. Type 5 phosphodiesterase inhibition in heart failure: the next step. J Am Coll Cardiol 50 (2007) 2145-2147
53. Rich S., and McLaughlin V.V. Endothelin receptor blockers in cardiovascular disease. Circulation 108 (2003) 2184-2190
54. Torre-Amione G., Young J.B., Colucci W.S., Lewis B.S., Pratt C., Cotter G., et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42 (2003) 140-147
55. Cotter G., Kaluski E., Stangl K., Pacher R., Richter C., Milo-Cotter O., et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 6 (2004) 601-609
56. Packer M., McMurray J., Massie B.M., Caspi A., Charlon V., Cohen-Solal A., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11 (2005) 12-20
57. Luscher T.F., Enseleit F., Pacher R., Mitrovic V., Schulze M.R., Willenbrock R., et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106 (2002) 2666-2672
58. Anand I., McMurray J., Cohn J.N., Konstam M.A., Notter T., Quitzau K., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
59. Pérez-Villa F., Cuppoletti A., Rossel V., Vallejos I., and Roig E. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin Transplant 20 (2006) 239-244
60. Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) [citado 10 Ene 2010] Disponible en: http://clinicaltrials.gov/ct2/show/NCT00763867?term#Phosphodiesterase5%Inhibition%to%Improve%Clinical&rank#1
61. Almenar L., Vicente J.L., Torregrosa S., Osa A., Martínez-Dolz L., Gómez-Plana J., et al. Variables predictoras de mortalidad precoz tras el trasplante cardíaco ortotópico en adultos. Rev Esp Cardiol 50 (1997) 628-634
62. López-Ciudad V.J., López Pérez J.M., Fojón Polanco S., Blanco Sierra F.J., Pradas Montilla G., Cuenca Castillo J.J., et al. Hipertensión pulmonar y mortalidad precoz después del trasplante cardíaco ortotópico. Rev Esp Cardiol 48 (1995) 552-556
63. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Keck B.M., and Hertz M.I. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report -2004. J Heart Lung Transplant 23 (2004) 796-803
64. Almenar Bonet L. Registro Español de Trasplante Cardiaco. XX Informe Oficial de la Sección de Insuficiencia Cardiaca y Trasplante Cardiaco de la Sociedad Española de Cardiología (1984-2008). Rev Esp Cardiol 62 (2009) 1286-1296
65. Chen J.M., Levin H.R., Michler R.E., Prusmack C.J., Rose E.A., and Aaronson K.D. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 114 (1997) 627-634
66. Costard-Jackle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19 (1992) 48-54
67. Costard-Jackle A., Hill I., Schroeder J.S., and Fowler M.B. The influence of preoperative patient characteristics on early and late survival following cardiac transplantation. Circulation 84 Suppl (1991) III329-III337
68. Delgado Jiménez J.F., Gómez Sánchez M.A., Calle Pérez G., Carnero Varo A., Hernández Afonso J., Tascón Pérez J., et al. Hipertensión arterial pulmonar y trasplante cardíaco: evolución hemodinámica y supervivencia. Rev Esp Cardiol 49 (1996) 804-809
69. Erickson K.W., Costanzo-Nordin M.R., O'Sullivan E.J., Johnson M.R., Zucker M.J., Pifarre R., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 9 (1990) 526-537
70. Murali S., Kormos R.L., Uretsky B.F., Schechter D., Reddy P.S., Denys B.G., et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 126 (1993) 896-904
71. Klotz S., Deng M.C., Hanafy D., Schmid C., Stypmann J., Schmidt C., et al. Reversible pulmonary hypertension in heart transplant candidates -pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail 5 (2003) 645-653
72. Mehra M.R., Kobashigawa J., Starling R., Russell S., Uber P.A., Parameshwar J., et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates -2006. J Heart Lung Transplant 25 (2006) 1024-1042
73. Torres J., Delgado J., Sanz J., González A., Sánchez V., Gámez S., et al. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. Transplant Proc 41 (2009) 2477-2479
74. Butler J., Stankewicz M.A., Wu J., Chomsky D.B., Howser R.L., Khadim G., et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant 24 (2005) 170-177
75. Stobierska-Dzierzek B., Awad H., and Michler R.E. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38 (2001) 923-931
76. Tedford R.J., Hemnes A.R., Russell S.D., Wittstein I.S., Mahmud M., Zaiman A.L., et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 1 (2008) 213-219